SCHEMBL660461

SCHEMBL660461

CCCC1CC(=O)N(Cn2c(-c3ccco3)nc3cc(C(F)(F)F)ccc32)C1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 10/20 0.39
KDM4E B2RXH2 6/20 0.39
HPGD P15428 5/20 0.39
HSD17B10 Q99714 4/20 0.39
TP53 P04637 2/20 0.39
SMN1; SMN2 Q16637 4/20 0.37
L3MBTL1 Q9Y468 1/20 0.36
TSHR P16473 6/20 0.35
TRPC5 Q9UL62 2/20 0.35
USP2 O75604 3/20 0.34
MAPT P10636 3/20 0.34
GAA P10253 2/20 0.34
MEN1 O00255 1/20 0.34
KMT2A Q03164 1/20 0.34
PKM P14618 2/20 0.33
NPC1 O15118 1/20 0.33
GLA P06280 1/20 0.33
ALOX15 P16050 1/20 0.33
NFKB1 P19838 1/20 0.33
RAB9A P51151 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20555013 0.87 KDM4E (0.32) ALDH1A1KDM4EHPGDHSD17B10TP53
SCHEMBL662213 0.85 KDM4E (0.37) ALDH1A1KDM4EHSD17B10SMN1; SMN2L3MBTL1
SCHEMBL662244 0.83 KDM4E (0.34) ALDH1A1KDM4ESMN1; SMN2L3MBTL1USP2
SCHEMBL662278 0.83 KDM4E (0.40) ALDH1A1KDM4EHPGDHSD17B10TP53
SCHEMBL5060899 0.82 CNR2 (0.42) ALDH1A1KDM4ESMN1; SMN2L3MBTL1USP2
SCHEMBL664185 0.82 CNR2 (0.40) KDM4ESMN1; SMN2L3MBTL1USP2CNR2
SCHEMBL662945 0.81 KCNK13 (0.34) KDM4ESMN1; SMN2L3MBTL1USP2CNR2
SCHEMBL661539 0.81 CNR2 (0.40) KDM4ESMN1; SMN2L3MBTL1USP2CNR2
SCHEMBL662275 0.81 CNR2 (0.38) KDM4ETP53SMN1; SMN2L3MBTL1TSHR
SCHEMBL4416624 0.79 CNR2 (0.54) ALDH1A1TP53SMN1; SMN2CNR2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 52 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7763644-B2 Imidazole derivatives, processes for preparing them and their uses UCB PHARMA, S.A. (BE) 2010-07-27 US claimed
EP-2050736-A1 Imidazole derivatives, processes for preparing them and their uses UCB Pharma, S.A. (BE) 2009-04-22 EP claimed
US-20080081832-A1 Imidazole derivatives, processes for preparing them and their uses UCB, S.A. 2008-04-03 US claimed
JP-2007513105-A 2007-05-24 JP claimed
CN-1906160-A Imidazole derivatives, processes for preparing them and their uses UCB SA (BE) 2007-01-31 CN claimed
EP-1706376-A1 IMIDAZOLE DERIVATIVES, PROCESSES FOR PREPARING THEM AND THEIR USES UCB, S.A. (BE) 2006-10-04 EP claimed
US-20050137241-A1 Imidazole derivatives, processes for preparing them and their uses UCB PHARMA, S.A. (BE) 2005-06-23 US claimed
WO-2005054188-A1 IMIDAZOLE DERIVATIVES, PROCESSES FOR PREPARING THEM AND THEIR USES UCB, S.A. (BE) 2005-06-16 WO claimed
US-20240293363-A1 METHODS AND COMPOSITIONS FOR IMPROVING COGNITIVE FUNCTION UNIV JOHNS HOPKINS (US) 2024-09-05 US disclosed
US-20230277501-A1 METHODS AND COMPOSITIONS FOR IMPROVING COGNITIVE FUNCTION THE JOHNS HOPKINS UNIVERSITY 2023-09-07 US disclosed
US-20230033195-A1 METHODS AND COMPOSITIONS FOR IMPROVING COGNITIVE FUNCTION THE JOHNS HOPKINS UNIVERSITY 2023-02-02 US disclosed
US-20220265685-A1 METHODS AND COMPOSITIONS FOR IMPROVING COGNITIVE FUNCTION THE JOHNS HOPKINS UNIVERSITY 2022-08-25 US disclosed
US-20220218665-A1 METHODS AND COMPOSITIONS FOR IMPROVING COGNITIVE FUNCTION UNIV JOHNS HOPKINS (US) 2022-07-14 US disclosed
US-11160785-B2 Methods and compositions for improving cognitive function AGENEBIO INC. (US) 2021-11-02 US disclosed
US-20080081832-A1 Imidazole derivatives, processes for preparing them and their uses UCB, S.A. 2008-04-03 US disclosed
US-7244747-B2 Imidazole derivatives, processes for preparing them and their uses UCB, S.A. (BE) 2007-07-17 US disclosed
CN-1906160-A Imidazole derivatives, processes for preparing them and their uses UCB SA (BE) 2007-01-31 CN disclosed
EP-1706376-A1 IMIDAZOLE DERIVATIVES, PROCESSES FOR PREPARING THEM AND THEIR USES UCB, S.A. (BE) 2006-10-04 EP disclosed
US-20050137241-A1 Imidazole derivatives, processes for preparing them and their uses UCB PHARMA, S.A. (BE) 2005-06-23 US disclosed
WO-2005054188-A1 IMIDAZOLE DERIVATIVES, PROCESSES FOR PREPARING THEM AND THEIR USES UCB, S.A. (BE) 2005-06-16 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11160785-B2 Methods and compositions for improving cognitive function BACE2, BACE1, GRIN2A ALDH1A1 1226/4885KDM4E 3701/4885HPGD 4659/4885
US-20240293363-A1 METHODS AND COMPOSITIONS FOR IMPROVING COGNITIVE FUNCTION BACE2, RAB2A, VAMP8 ALDH1A1 2819/4885KDM4E 802/4885HPGD 3278/4885
US-20220218665-A1 METHODS AND COMPOSITIONS FOR IMPROVING COGNITIVE FUNCTION BACE2, RAB2A, VAMP8 ALDH1A1 2819/4885KDM4E 802/4885HPGD 3278/4885
US-20230277501-A1 METHODS AND COMPOSITIONS FOR IMPROVING COGNITIVE FUNCTION GRIN2A, CHRNA2, SYNGR2 ALDH1A1 2177/4885KDM4E 1177/4885HPGD 3988/4885
US-20220265685-A1 METHODS AND COMPOSITIONS FOR IMPROVING COGNITIVE FUNCTION BACE1, BACE2, ACHE ALDH1A1 2614/4885KDM4E 3495/4885HPGD 3898/4885
US-20080081832-A1 Imidazole derivatives, processes for preparing them and their uses CYP3A4, PPIP5K2, CYP2C19 ALDH1A1 896/4885KDM4E 783/4885HPGD 79/4885
US-20230033195-A1 METHODS AND COMPOSITIONS FOR IMPROVING COGNITIVE FUNCTION GRIN2D, GRIN2A, SLC18A2 ALDH1A1 2755/4885KDM4E 3554/4885HPGD 3683/4885
US-20050137241-A1 Imidazole derivatives, processes for preparing them and their uses CYP3A4, PPIP5K2, CYP2C19 ALDH1A1 896/4885KDM4E 783/4885HPGD 79/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.